Prognostic factors in patients with stage IV non-small cell lung cancer

Chinese-German Journal of Clinical Oncology

Volumn 5, Issue 5, 2006, Pages 319-323

  Ma, Meili ^a   Shen, Jie ^a   Jiang, Liyan ^a   Han, Baohui ^a   Bai, Hao ^a   Ji, Hao ^a   Zhao, Yizuo ^a   Jin, Bo ^a   Yu, Yongfeng ^a   Pei, Jun ^a   Zhang, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Metastasis; Multivariate analysis; Non small cell lung cancer; Prognosis

Indexed keywords

EID: 33846447398     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-006-0520-z     Document Type: Article

References (23)

1. Kochanek KD, Murphy SL, Anderson RN, et al. Deaths: Final data for 2002. Natl Vital Stat Rep, 2004, 53: 1-11.
2. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 2003, 123 (1 Suppl): 226S-243S. Review.
3. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med, 1990, 322: 494-500.
4. Kondziolka D, Lunsford LD, Flickinger JC, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastses. Int J Radiat Oncol Biol Phys, 1999, 45: 427-434.
5. Pfister DG, JohnsOn DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of Unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol, 2004, 22: 330-353.
6. Luketich JD, Burt ME. Does resection of adrenal metastases from nonsmall cell lung cancer improve survival? Ann Thorac Surg, 1996, 62: 1614-1616.
7. Schuchert MJ, Luketich JD. Solitary sites of metastatic disease in non-small cell lung cancer. Curr Treat Options Oncol, 2003, 4: 65-79. Review.
8. Lanzotti, VJ, Thomas DR, Boyle, LE, et al. Survival with inoperable lung cancer: An integration of prognostic variables based on simple clinical criteria. Cancer, 1977, 39: 303-313.
9. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst, 1980, 65: 25-32.
10. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol, 1986, 4: 1604-1614.
11. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol, 1986, 4: 702-709.
12. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol, 1986, 4: 14-22.
13. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol, 1989, 7: 1602-1613.
14. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin vs cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol. 1989, 7: 1087-1092.
15. Leudke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non-smallcell lung cancer: A Southeastern Cancer Study Group Trial. J Clin Oncol, 1990, 8: 886-891.
16. Miller TP, Chen TT, Coltman CA Jr, et al. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large cell and adenocarcinoma of the lung: A Southwest Oncology Group Study. J Clin Oncol, 1986, 4: 502-508.
17. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group Experience. J Clin Oncol, 1991, 9: 1618-1626.
18. Liu NS, Spitz MR, Kemp BL, et al. Adenocarcinoma of the lung in young patients: The MD Anderson experience. Cancer, 2000, 88: 1837-1841.
19. Kim K, Bonomi P, Kargler J, et al. Two-year survival and prognostic factors for overall survival in advanced NSCLC: An ECOG experience [abstract]. Proc Am Soc Clin Oncol, 1998; 17,461a.
20. Herndon JE, Fleishman S, Kornblith AB, et al. Is quality of life predictive of survival of patients with advanced NSCLC? Cancer, 1999, 85: 333-340.
21. Vigano A, Binera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med, 2000, 160: 861-868.
22. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol, 1989, 7: 1398-1406.
23. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol, 1988, 6: 633-641.